Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: A three-year clinical experience

Artificial Organs

Volumn 35, Issue 12, 2011, Pages 1186-1193

  Lucchi, Leonardo ^a   Carboni, Chiara ^a   Stipo, Lucia ^a   Malaguti, Vittoria ^a   Ferrari, Federica ^a   Graziani, Romina ^a   Arletti, Silvia ^a   Graziosi, Catia ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cinacalcet; Hemodialysis; Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation targets; Secondary hyperparathyroidism

Indexed keywords

BINDERS; DIALYSIS; DISEASES; HEMODIALYZERS; PATIENT TREATMENT; PHOSPHORUS; VITAMINS;

CINACALCET; HAEMODIALYSIS; HYPERPARATHYROIDISM; KIDNEY DISEASE; KIDNEY DISEASE OUTCOME QUALITY INITIATIVE OF THE NATIONAL KIDNEY FOUNDATION TARGET; OUTCOME QUALITY; PARATHYROID HORMONES; PHOSPHATE BINDERS; QUALITY INITIATIVES; SECONDARY HYPERPARATHYROIDISM;

CALCIUM;

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; VITAMIN D; NAPHTHALENE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; EARLY INTERVENTION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS;

EID: 84857971781     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2011.01270.x     Document Type: Article

References (31)

1. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945–53.
2. Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007;18:875–85.
3. Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail 2003;25:595–602.
4. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:396–9.
5. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478–83.
6. Tarrass F, Benjelloun M, Zamd M, et al. Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors. Nephrology (Carlton) 2006;11:494–6.
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–18.
8. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179–87.
9. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423–9.
10. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxivitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92: 1436–43.
11. Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328–36.
12. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005;288:F253–64.
13. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2003;42(Suppl. 3):S1–170.
14. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44(Suppl. 2):34–8.
15. Moe SM, Drüeke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003;23:369–79.
16. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004;308:627–35.
17. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575–83.
18. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516–25.
19. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800–7.
20. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46:58–67.
21. Torres PU. Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 2004;19(Suppl. 5):27–33.
22. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/ DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760–71.
23. Lazar E, Hebert K, Poma T, Stankus N. Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism. Am J Nephrol 2007;27: 274–8.
24. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005;20:2186–93.
25. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24:982–9.
26. Arenas MD, Alvarez-Ude F, Gil MT, et al. Implementation of “K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease” after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007;22: 1639–44.
27. Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36–45.
28. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793–800.
29. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898–905.
30. Sprague SM, Evenepoel P, Curzi MP, et al. Simultaneous control of PTH and CaxP is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 2009;4:1465–76.
31. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345–50.